Prior studies have shown that PL’s novel proteoglycan (P1) inhibits colorectal cancer by boosting the immune response to T cells and IgA, and by disrupting the Reg IV/EGFR/Akt signaling pathway. Here, AKT1 is linked to colorectal cancer.